Literature DB >> 22167652

Effects of chronic guanosine treatment on hippocampal damage and cognitive impairment of rats submitted to chronic cerebral hypoperfusion.

Marcelo Ganzella1, Enderson Dias Alves de Oliveira, Daniel Diniz Comassetto, Fernanda Cechetti, Victor Hermes Cereser, Júlia Dubois Moreira, Gisele Hansel, Roberto Farina Almeida, Denise Barbosa Ramos, Yanier Nuñes Figueredo, Debora Guerini Souza, Jean Pierre Oses, Paulo Valdeci Worm, Matilde Achaval, Carlos Alexandre Netto, Diogo Onofre Souza.   

Abstract

Chronic cerebral hypoperfusion contributes to a cognitive decline related to brain disorders. Its experimental model in rats is a permanent bilateral common carotid artery occlusion (2VO). Overstimulation of the glutamatergic system excitotoxicity due to brain energetic disturbance in 2VO animals seems to play a pivotal role as a mechanism of cerebral damage. The nucleoside guanosine (GUO) exerts extracellular effects including antagonism of glutamatergic activity. Accordingly, our group demonstrated several neuroprotective effects of GUO against glutamatergic excitotoxicity. Therefore, in this study, we evaluated a chronic GUO treatment effects in rats submitted to 2VO. We evaluated the animals performance in the Morris water maze and hippocampal damage by neurons and astrocytes immunohistochemistry. In addition, we investigated the cerebrospinal fluid (CSF) brain derived neurotrophic factor (BDNF) and serum S100B levels. Additionally, the purine CSF and plasma levels were determined. GUO treatment did not prevent the cognitive impairment promoted by 2VO. However, none of the 2VO animals treated with GUO showed differences in the hippocampal regions compared to control, while 20% of 2VO rats not treated with GUO presented loss of pyramidal neurons and increased glial labeling cells in CA1 hippocampal region. In addition, we did not observe differences in CSF BDNF nor serum S100B levels among the groups. Of note, both the 2VO surgery and GUO treatment changed the purine CSF and plasma profile. In conclusion, GUO treatment did not prevent the cognitive impairment observed in 2VO animals, but our data suggest that GUO could be neuroprotective against hippocampal damage induced by 2VO.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22167652     DOI: 10.1007/s10072-011-0872-1

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  83 in total

1.  S100B and NSE serum levels in patients with Parkinson's disease.

Authors:  Débora V Schaf; Adriano B L Tort; Daniele Fricke; Pedro Schestatsky; Luis V C Portela; Diogo O Souza; Carlos R M Rieder
Journal:  Parkinsonism Relat Disord       Date:  2005-01       Impact factor: 4.891

Review 2.  Cerebral microvascular pathology in aging and Alzheimer's disease.

Authors:  E Farkas; P G Luiten
Journal:  Prog Neurobiol       Date:  2001-08       Impact factor: 11.685

3.  Prevalence and outcomes of vascular cognitive impairment. Vascular Cognitive Impairment Investigators of the Canadian Study of Health and Aging.

Authors:  K Rockwood; C Wentzel; V Hachinski; D B Hogan; C MacKnight; I McDowell
Journal:  Neurology       Date:  2000-01-25       Impact factor: 9.910

4.  Decreased levels of BDNF protein in Alzheimer temporal cortex are independent of BDNF polymorphisms.

Authors:  Jung Lee; Hiroaki Fukumoto; Jennifer Orne; Jochen Klucken; Susan Raju; Charles R Vanderburg; Michael C Irizarry; Bradley T Hyman; Martin Ingelsson
Journal:  Exp Neurol       Date:  2005-07       Impact factor: 5.330

5.  Local cerebral glucose utilisation following acute and chronic bilateral carotid artery ligation in Wistar rats: relation to changes in local cerebral blood flow.

Authors:  M Tsuchiya; K Sako; S Yura; Y Yonemasu
Journal:  Exp Brain Res       Date:  1993       Impact factor: 1.972

6.  Ischemic damage visualized in flat mounts of rat retina after photochemically induced thrombosis.

Authors:  R Schmidt-Kastner; U T Eysel
Journal:  Brain Res Bull       Date:  1994       Impact factor: 4.077

7.  Quinolinic acid promotes seizures and decreases glutamate uptake in young rats: reversal by orally administered guanosine.

Authors:  Diogo Losch de Oliveira; Joel Felipe Horn; Juliana Moura Rodrigues; Marcos E S Frizzo; Emílio Moriguchi; Diogo Onofre Souza; Susana Wofchuk
Journal:  Brain Res       Date:  2004-08-20       Impact factor: 3.252

8.  Oral administration of guanosine impairs inhibitory avoidance performance in rats and mice.

Authors:  Elsa Regina Vinadé; Ivan Izquierdo; Diogo Rizzato Lara; André Prato Schmidt; Diogo Onofre Souza
Journal:  Neurobiol Learn Mem       Date:  2004-03       Impact factor: 2.877

9.  Neuroprotection by cilostazol, a phosphodiesterase type 3 inhibitor, against apoptotic white matter changes in rat after chronic cerebral hypoperfusion.

Authors:  Jeong Hyun Lee; So Youn Park; Yung Woo Shin; Ki Whan Hong; Chi Dae Kim; Sang-Min Sung; Ki Young Kim; Won Suk Lee
Journal:  Brain Res       Date:  2006-03-03       Impact factor: 3.252

10.  Guanosine stimulates neurite outgrowth in PC12 cells via activation of heme oxygenase and cyclic GMP.

Authors:  Christian Bau; Pamela J Middlemiss; Shaun Hindley; Shucui Jiang; Renata Ciccarelli; Francesco Caciagli; Patrizia Diiorio; Eva S Werstiuk; Michel P Rathbone
Journal:  Purinergic Signal       Date:  2005-03-07       Impact factor: 3.765

View more
  19 in total

1.  Neuroprotective Effects of Guanosine Administration on In Vivo Cortical Focal Ischemia in Female and Male Wistar Rats.

Authors:  Luciele Varaschini Teixeira; Roberto Farina Almeida; Francieli Rohden; Leo Anderson Meira Martins; Poli Mara Spritzer; Diogo Onofre Gomes de Souza
Journal:  Neurochem Res       Date:  2018-05-31       Impact factor: 3.996

2.  Anti-aging effects of guanosine in glial cells.

Authors:  Débora Guerini Souza; Bruna Bellaver; Larissa Daniele Bobermin; Diogo Onofre Souza; André Quincozes-Santos
Journal:  Purinergic Signal       Date:  2016-09-01       Impact factor: 3.765

Review 3.  Neuroprotective Effects of Guanosine in Ischemic Stroke-Small Steps towards Effective Therapy.

Authors:  Karol Chojnowski; Mikolaj Opielka; Wojciech Nazar; Przemyslaw Kowianski; Ryszard T Smolenski
Journal:  Int J Mol Sci       Date:  2021-06-27       Impact factor: 5.923

4.  Guanosine inhibits LPS-induced pro-inflammatory response and oxidative stress in hippocampal astrocytes through the heme oxygenase-1 pathway.

Authors:  Bruna Bellaver; Débora Guerini Souza; Larissa Daniele Bobermin; Carlos-Alberto Gonçalves; Diogo Onofre Souza; André Quincozes-Santos
Journal:  Purinergic Signal       Date:  2015-10-02       Impact factor: 3.765

5.  Intranasal guanosine administration presents a wide therapeutic time window to reduce brain damage induced by permanent ischemia in rats.

Authors:  Denise Barbosa Ramos; Gabriel Cardozo Muller; Guilherme Botter Maio Rocha; Gustavo Hirata Dellavia; Roberto Farina Almeida; Leticia Ferreira Pettenuzzo; Samanta Oliveira Loureiro; Gisele Hansel; Ângelo Cássio Magalhães Horn; Diogo Onofre Souza; Marcelo Ganzella
Journal:  Purinergic Signal       Date:  2015-12-23       Impact factor: 3.765

6.  Altered expression of neurofilament 200 and amyloid-β peptide (1-40) in a rat model of chronic cerebral hypoperfusion.

Authors:  Weihua Liang; Weiwei Zhang; Shifu Zhao; Qianning Li; Hua Liang; Rongchuan Ceng
Journal:  Neurol Sci       Date:  2014-12-02       Impact factor: 3.307

7.  Bone marrow mononuclear cell transplantation promotes therapeutic angiogenesis via upregulation of the VEGF-VEGFR2 signaling pathway in a rat model of vascular dementia.

Authors:  Jianping Wang; Xiaojie Fu; Chao Jiang; Lie Yu; Menghan Wang; Wei Han; Liu Liu; Jian Wang
Journal:  Behav Brain Res       Date:  2014-02-28       Impact factor: 3.332

Review 8.  Guanosine and its role in neuropathologies.

Authors:  Luis E B Bettio; Joana Gil-Mohapel; Ana Lúcia S Rodrigues
Journal:  Purinergic Signal       Date:  2016-03-22       Impact factor: 3.765

9.  Gliopreventive effects of guanosine against glucose deprivation in vitro.

Authors:  André Quincozes-Santos; Larissa Daniele Bobermin; Débora Guerini de Souza; Bruna Bellaver; Carlos-Alberto Gonçalves; Diogo Onofre Souza
Journal:  Purinergic Signal       Date:  2013-07-12       Impact factor: 3.765

Review 10.  The Guanine-Based Purinergic System: The Tale of An Orphan Neuromodulation.

Authors:  Valentina Di Liberto; Giuseppa Mudò; Roberta Garozzo; Monica Frinchi; Víctor Fernandez-Dueñas; Patrizia Di Iorio; Renata Ciccarelli; Francesco Caciagli; Daniele F Condorelli; Francisco Ciruela; Natale Belluardo
Journal:  Front Pharmacol       Date:  2016-06-17       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.